Avoid Errors With the New Monoclonal Antibodies for COVID-19

January 2021

Bamlanivimab and casirivimab/imdevimab will be the first meds authorized to treat OUTPATIENTS with COVID-19.

These new monoclonal antibodies, or "mabs," block the virus that causes COVID-19...SARS-CoV-2...from entering cells.

Both meds are single-dose IV infusions given over 1 hour.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote